NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Average Recommendation of “Moderate Buy” by Analysts

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has received an average recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $38.25.

A number of equities analysts have recently issued reports on the company. BTIG Research reissued a “buy” rating and set a $25.00 price target on shares of NRx Pharmaceuticals in a research report on Tuesday, March 24th. HC Wainwright restated a “buy” rating and issued a $45.00 price objective on shares of NRx Pharmaceuticals in a report on Monday, April 27th. D. Boral Capital reaffirmed a “buy” rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday, May 5th. Zacks Research upgraded shares of NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, March 2nd. Finally, Ascendiant Capital Markets raised their target price on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the company a “buy” rating in a research report on Monday, April 27th.

Hedge Funds Weigh In On NRx Pharmaceuticals

Several institutional investors have recently bought and sold shares of the business. Ethos Financial Group LLC raised its stake in NRx Pharmaceuticals by 33.6% in the first quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock worth $34,000 after buying an additional 4,000 shares in the last quarter. One Wealth Management Investment & Advisory Services LLC boosted its position in NRx Pharmaceuticals by 35.3% during the 4th quarter. One Wealth Management Investment & Advisory Services LLC now owns 37,873 shares of the company’s stock valued at $103,000 after acquiring an additional 9,882 shares in the last quarter. State Street Corp increased its holdings in shares of NRx Pharmaceuticals by 14.0% in the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock valued at $236,000 after acquiring an additional 10,700 shares during the period. Sjbenen Advisory LLC purchased a new position in shares of NRx Pharmaceuticals in the 4th quarter valued at $41,000. Finally, Two Sigma Investments LP raised its position in shares of NRx Pharmaceuticals by 66.4% in the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after acquiring an additional 20,880 shares in the last quarter. 4.27% of the stock is owned by hedge funds and other institutional investors.

NRx Pharmaceuticals Stock Performance

NRx Pharmaceuticals stock opened at $2.95 on Thursday. The company has a market capitalization of $97.56 million, a PE ratio of -2.12 and a beta of 2.02. The company has a 50 day moving average price of $2.37 and a 200-day moving average price of $2.31. NRx Pharmaceuticals has a fifty-two week low of $1.62 and a fifty-two week high of $3.84.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its quarterly earnings data on Monday, March 23rd. The company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.28. The firm had revenue of $0.98 million during the quarter, compared to the consensus estimate of $7.53 million. On average, analysts forecast that NRx Pharmaceuticals will post 0.13 earnings per share for the current year.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.